What is NOVACC?
NOVACC is a new, patented, wearable device that is different from current masks. While existing masks attempt to block the penetration of viral particles, most are ineffective in protecting against aerosol particles completely. The NOVACC device actually KILLS the virus, rather than only attempting to block the viral particles.
The bottom line is this: you can wash hands thoroughly, social distance, wear current masks, be vaccinated, and still become infected and transmit the virus.
NOVACC is designed and engineered to prevent both infection and transmission.
Not only is NOVACC safer* and and more effective** than vaccines, when used as intended, it is also a solution for those unable to take a vaccine.
The idea has been vetted by doctors, nurses, the U.S. Food and Drug Administration (FDA), Georgia Institute of Technology (Georgia Tech), Global Center for Medical Innovation (GCMI) , and the Georgia governor’s office. In addition to unanimous positive feedback from the above, many have not only offered support but have now stepped in to partner with NOVACC to develop, build and test the prototype.
Key partnerships have led to increased momentum to expedite the prototype development, testing and final product.
The current partnership with Georgia Tech and GCMI is providing valuable medical, technological, regulatory, engineering and commercialization experts that will expedite development, production and distribution of NOVACC.
Because of NOVACC’s potential to save millions of lives, time is of the essence.
The goal of the NOVACC product development team is to create a wearable device that can be efficiently manufactured and made available for sale at a cost not to exceed $100. By keeping the cost below that of a typical cellular telephone, the product is affordable for practically every consumer.
* There are no known side effects from wearing the NOVACC device.
** Using the NOVACC device as designed will prevent both getting and spreading respiratory viruses such as COVID.
How does NOVACC work?
Due to the proprietary intelligence and processes involved, specific details cannot be provided at this stage of development.
The “simple” explanation is that inhaled air enters into an environment in which viral particles cannot survive. As air enters the body, this means no live virus is inhaled into the lungs. In reverse, exhaled air goes through the same process to kill all live viral and even bacterial particles. In essence, mankind will serve as an air filter for the planet, to cleanse live viruses from the atmosphere.
Who will be most interested in NOVACC?
First responders, doctors, nurses
Nursing homes, assisted living centers
Entertainment venues that host events like concerts and sporting events
Centers and houses of worship including churches, synagogues and mosques
Airline, ship & rail travel
Military
People with compromised immune systems
People who can’t take vaccines whether for medical or religious reasons
EVERYONE
How does NOVACC compare to current solutions?
With no vaccine and no mask, virus particles enter the body and attach to the lungs, which is how a person gets infected with any respiratory virus.
With a vaccine, even if an individual chooses to wear a cloth covering or mask, live virus particles are still inhaled and reach the lungs. Virus particles are also exhaled and transmission is still possible.
The patent pending NOVACC device works by killing virus particles before they enter the nostrils and attach to the lungs, thus preventing infection. Transmission of the virus is also stopped since the individual can’t exhale live virus.
